With respect to protein expression, patients with only 5–10% wildtype a3 protein expression can progress past the infantile mortality normally associated with a3 mutations; however, these patients still present with osteopetrosis, as well as vision and hearing loss [97,111,112]. This evidence concerns the gene TCIRG1 and osteopetrosis.